- Home
- MDGL vs HALO Comparison
MDGL vs HALO Comparison
Compare MDGL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- HALO
- Stock Information
- Founded
- MDGL 2011
- HALO 1998
- Country
- MDGL United States
- HALO United States
- Employees
- MDGL N/A
- HALO N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDGL Health Care
- HALO Health Care
- Exchange
- MDGL Nasdaq
- HALO Nasdaq
- Market Cap
- MDGL 6.8B
- HALO 7.4B
- IPO Year
- MDGL N/A
- HALO N/A
- Fundamental
- Price
- MDGL $319.93
- HALO $59.25
- Analyst Decision
- MDGL Buy
- HALO Buy
- Analyst Count
- MDGL 9
- HALO 9
- Target Price
- MDGL $386.29
- HALO $61.75
- AVG Volume (30 Days)
- MDGL 333.2K
- HALO 1.6M
- Earning Date
- MDGL 05-01-2025
- HALO 05-06-2025
- Dividend Yield
- MDGL N/A
- HALO N/A
- EPS Growth
- MDGL N/A
- HALO 63.33
- EPS
- MDGL N/A
- HALO 3.43
- Revenue
- MDGL $180,133,000.00
- HALO $1,015,324,000.00
- Revenue This Year
- MDGL $230.69
- HALO $20.06
- Revenue Next Year
- MDGL $74.76
- HALO $24.04
- P/E Ratio
- MDGL N/A
- HALO $17.27
- Revenue Growth
- MDGL N/A
- HALO 22.44
- 52 Week Low
- MDGL $189.00
- HALO $37.97
- 52 Week High
- MDGL $377.46
- HALO $66.00
- Technical
- Relative Strength Index (RSI)
- MDGL 50.76
- HALO 47.19
- Support Level
- MDGL $276.20
- HALO $56.47
- Resistance Level
- MDGL $330.64
- HALO $62.14
- Average True Range (ATR)
- MDGL 20.79
- HALO 2.84
- MACD
- MDGL 0.06
- HALO -0.27
- Stochastic Oscillator
- MDGL 76.56
- HALO 55.05
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.